IFNA1 and B-cell chronic lymphocytic leukemia: Evidence for ongoing activity of type 1 and 2 interferons in CLL patients on ibrutinib has been found previously5 and the studies reported here suggest CLL cells experience IFN signaling while on ibrutinib in vivo that is turned off by ruxolitinib (Figure 3A).